Ciba Consumer's Transderm Scop
Executive Summary
Firm requests that the 24-hour version of its motion sickness drug, containing 1 mg of scopolamine, be considered ANDA suitable. Ciba says release rate of 24-hour version is equivalent to the original 72-hour Transderm Scop (1.5 mg scopolamine) which is on FDA's list of ANDA suitable drugs.